G1 Therapeutics, Inc. (NASDAQ:GTHX) is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.3 per share from $ 28.57 million in revenue.
For the full year, analysts predict revenues of $ 27.09 million, while looking forward to loss of $ 2.91 per share.
Previous Quarter Performance
G1 Therapeutics, Inc. posted loss for the second quarter of $ 0.83 per share, from the revenue of $ 2.14 million. Wall street analysts are predicting, GTHX to report 2Q20 loss of $ 0.83 per share from revenue of $ 2.25 million. The top line results fell short of analysts by $ 0.11 million or 4.89 percent.
Stock Performance
Shares of G1 Therapeutics, Inc. traded up $ 0.38 or 3.39 percent on Tuesday, reaching $ 11.59 with volume of 2.38 million shares. G1 Therapeutics, Inc. has traded high as $ 11.76 and has cracked $ 11.32 on the downward trend
According to the previous trading day, closing price of $ 11.59, representing a 27.39 % increase from the 52 week low of $ 8.80 and a 64.28 % decrease over the 52 week high of $ 31.38.
The company has a market capital of $ 440.59 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
G1 Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.g1therapeutics.com
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
